Literature DB >> 8794893

Cyclic AMP-dependent phosphodiesterase isozyme-specific potentiation by protein kinase C in hypertrophic cardiomyopathic hamster hearts.

H Yu1, J J Cai, H C Lee.   

Abstract

We recently reported that protein kinase C (PKC) potentiates cAMP-dependent phosphodiesterase (PDE) activity in Syrian hamster hearts with hypertrophic cardiomyopathy (HCM) but not in control hamster hearts. In this study, we examined the mechanism of this PKC/PDE interaction by identifying the PDE isozyme that is the target of PKC modulation. Using Mono-Q high performance liquid chromatography, both control and HCM hamster cardiac PDE could be partially purified into the calcium/calmodulin-dependent (I), the cGMP-stimulated (II), and the low KM (III) isozyme fractions. The elution profiles of PDE isozyme fractions were similar to those in isolated hamster cardiac myocytes. The percentages of PDE isozymes activities (I/II/III) were 68.8:22.4:8.8% and 51.1:38.4:10.5% for HCM and control hearts, respectively (n = 4), suggesting a change in the quantitative expression of isozymes activities in HCM hearts with a significant increase in the calcium/calmodulin-dependent PDE isozyme activities (p < 0.05 compared with control). The addition of exogenous PKC (100 munits of rat brain) produced a 60% stimulation in the calcium/calmodulin-dependent PDE isozyme fraction but not in other PDE isozymes of HCM and in none of the isozymes in control hearts. This PKC-mediated potentiation of the calcium/calmodulin-dependent PDE activity was completely blocked by the PKC-specific peptide inhibitor PKC(19-31). Analysis of enzymatic kinetics showed that PKC enhanced the calcium/calmodulin-dependent PDE isozyme activity in HCM by increasing its Vmax (from 350 pmol/mg/min at baseline to 758 pmol/min/mg with PKC) without changing its KM (0.69 microM at baseline versus 0.89 microM with PKC). These results suggest that there are both quantitative and qualitative abnormalities in the expression of the calcium/ calmodulin-dependent PDE isozyme in HCM hearts and that the PKC modulation of PDE activity in the HCM heart is isozyme specific.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794893

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  2 in total

1.  Potentiation of receptor-mediated cAMP production: role in the cross-talk between vasopressin V1a and V2 receptor transduction pathways.

Authors:  C Klingler; N Ancellin; M B Barrault; A Morel; B Corman
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

2.  Protein kinase C-mediated phosphorylation and activation of PDE3A regulate cAMP levels in human platelets.

Authors:  Roger W Hunter; Carol Mackintosh; Ingeborg Hers
Journal:  J Biol Chem       Date:  2009-03-04       Impact factor: 5.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.